Assessing the Efficacy and Safety of Rosiglitazone Added to Standard Therapy for Hepatitis C Genotype 1 With Fatty Liver

NCT00274495 · clinicaltrials.gov ↗

PHASE4

Phase

TERMINATED

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Chronic Hepatitis C Infection
Fatty Liver

Interventions

DRUG: Rosiglitazone and Pegasys/Ribavirin

Sponsor

Beth Israel Medical Center